United States Viral Vector and Plasmid DNA Testing Services Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global viral vector and plasmid DNA testing services market reached US$ 228.83 million in 2023, with a rise of US$ 291.13 million in 2024, and is expected to reach US$ 1,966.46 million by 2033, growing at a CAGR of 23.2% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/viral-vector-and-plasmid-dna-testing-services-market?sb

Key Development:

United States: Recent Viral Vector & Plasmid DNA Testing/Services Developments

✅ In December 2025, ViGeneron and WuXi Advanced Therapies announced a strategic partnership to accelerate production for the clinical development of VG901, a next‐generation ophthalmic gene therapy program, boosting capacity and throughput for viral vector and plasmid DNA testing and manufacturing.

✅ In August 2025, ProBio expanded its GMP AAV production services at its Hopewell, New Jersey facility integrating viral vector production with plasmid DNA testing workflows to support faster and more robust gene therapy development timelines.

✅ In August 2025, Bionova Scientific inaugurated a new plasmid DNA facility in The Woodlands, Texas, enhancing support for mRNA, viral vector‐based cell and gene therapy development, and including expanded analytical testing services for quality and purity.

✅ In September 2025, There is a rising demand for advanced viral vector and plasmid DNA testing services in the U.S., driven by an expanding gene therapy pipeline requiring high‐quality safety, identity, potency, and genetic characterization analyses.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=viral-vector-and-plasmid-dna-testing-services-market

Japan: Recent Viral Vector & Plasmid DNA Testing/Services Developments

✅ In November 2025, Japan's viral vector and plasmid DNA testing services market saw intensified adoption of advanced analytical methods including AI‐assisted sequencing and digital PCR to enhance viral vector characterization accuracy and plasmid quality control, supporting gene therapy and DNA vaccine pipelines.

✅ In November 2025, demand for stringent viral vector testing and plasmid DNA integrity analysis increased as Japanese biotech and academic institutions upscale R&D and clinical trial programs for new gene‐based therapeutics, pushing service providers to expand high‐throughput testing workflows.

✅ In October 2025, Japan's plasmid DNA testing segment is becoming more critical for ensuring therapeutic safety and regulatory compliance, especially for plasmid‐based gene therapies and DNA vaccines driving growth in specialized test services.

✅ In October 2025, Growing collaboration between Japanese research organizations and service providers aimed at optimizing viral vector and plasmid DNA workflows - improving turnaround time and analytical reproducibility in testing services that underpin advanced therapies.

Europe: Recent Viral Vector & Plasmid DNA Testing/Services Developments

✅ In December 2025, multi‐omics‐guided bioprocess optimization approaches (combining transcriptomics, proteomics, metabolomics) gained traction among European CDMOs to enhance yield and analytical quality control for viral vectors and plasmid DNA, marking a shift toward more efficient testing and quality services.

✅ In November 2025, European contract development and manufacturing organizations continued expanding large‐scale single‐use bioreactor capacity tailored for viral vector and plasmid DNA manufacturing strengthening regional service offerings that include advanced testing and analytics.

✅ In 2025, several European nations advanced public‐private initiatives under Horizon Europe to support gene and cell therapy supply chains including infrastructure investments aimed at boosting viral vector/plasmid DNA production and testing capabilities to meet rising clinical demand.

✅ In 2025, Europe's CDMOs are progressively adopting digital and automated quality testing platforms (e.g., real‐time process monitoring) to enhance consistency and speed of viral vector and plasmid DNA testing workflows used by biotech and pharma clients.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/viral-vector-and-plasmid-dna-testing-services-market?sb

Key Players:

=> Charles River Laboratories, Thermo Fisher Scientific Inc., Merck KGaA, PathoQuest, Coriolis Pharma, Lonza, AGC Biologics, Exothera, Batavia Biosciences B.V. and ReiThera srl, among others.

Key Segments:

By Service Type

Viral Vector Testing Services - ~30% share, essential for cell & gene therapy and viral vector-based vaccine development.
Plasmid DNA Testing Services - ~35% share, critical for DNA-based therapeutics and research applications.
Research-grade Plasmid DNA Testing - ~20% share, used in early-stage R&D and academic research.
GMP-grade Plasmid DNA Testing - ~15% share, compliant with regulatory standards for clinical trials and manufacturing.

By Testing Stage

Upstream Testing - ~45% share, includes testing of raw materials, cell lines, and viral vectors before production.
Downstream Testing - ~55% share, covers purification, quality control, and final product testing.

By Application

Analytical & Quality Control Services - ~30% share, ensures product safety and regulatory compliance.
Cell & Gene Therapy Development - ~25% share, supports novel therapeutic pipelines.
Vaccine Development (viral vector-based and DNA vaccines) - ~20% share, critical for biopharmaceutical innovation.
Preclinical Research & Discovery - ~15% share, enables early-stage drug discovery and validation.
Clinical Trial Material Testing - ~10% share, ensures GMP-grade product readiness for human trials.

By End-User

Pharmaceutical & Biopharmaceutical Companies - ~40% share, primary drivers of testing services.
Contract Development & Manufacturing Organizations (CDMOs) - ~25% share, outsourcing growth fuels demand.
Contract Research Organizations (CROs) - ~20% share, key partners for clinical and preclinical testing.
Academic & Research Institutes - ~15% share, support research-grade and discovery-stage testing.

By Region

North America - ~35% Share
Dominated by pharma innovation hubs and strong cell & gene therapy ecosystem.

Europe - ~25% Share
Growth fueled by biotech clusters, clinical trials, and regulatory compliance initiatives.

Asia-Pacific - ~30% Share
Rapid expansion due to increasing CDMO presence, R&D investments, and vaccine development programs.

South America - ~5% Share
Emerging research initiatives and partnerships drive moderate market adoption.

Middle East & Africa - ~5% Share
Market expansion primarily through academic research and early-stage clinical collaborations.

FAQ

What is the current size of the Viral vector and plasmid DNA testing services Market?

A: In 2024, the Viral vector and plasmid DNA testing services Market was valued at US$ 291.13 million, reflecting its strong industry presence.

Q2: How large is the Viral vector and plasmid DNA testing services Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Viral vector and plasmid DNA testing services Market will grow to around US$ 1,966.46 million , demonstrating significant expansion.

Q3: What is the growth rate of the Viral vector and plasmid DNA testing services Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 23.2% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.